Enanta制药 ENTA 深 沪
等待开盘 08-29 09:30:00 美东时间
8.695
+0.165
+1.93%
华盛通- 最 高8.79
- 今 开8.54
- 成交量 3.50万股
- 最 低 8.51
- 昨 收 8.53
- 总市值 1.86亿
- 52周最高 13.3699
- 市盈率 静 --
- 换手率 0.16%
- 52周最低 4.09
- 委 比 98.54%
- 总股本 2137.66万
- 历史最高 127.77
- 量 比 0.43
- 振 幅 3.28%
- 历史最低 4.09
- 每 手 1
- 风险率 2.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Enanta Pharmaceuticals Appoints Harry R. Trout As Interim Principal Financial Officer
- SEC Filing
08-28 05:01
北大女博士罕见发声：11年前买了贵州茅台20万元，到现在能赚了多少？从贫穷到富有全过程
（来源：A股荟萃） 目前A股市场上最贵的股票非茅台莫属了，而且茅台的股价在“A股最贵”的这个位置上可以说是经久不衰。虽然曾经也有过不少上市公司的股票价格超过茅台...
08-27 16:23
Enanta Sues Pfizer in European Court Over Patent Linked to COVID Drug Paxlovid
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, announced today that it has filed suit
08-20 19:08
CISCO REPORTS FOURTH QUARTER AND FISCAL YEAR 2025 EARNINGS
SAN JOSE, Calif., Aug. 13, 2025 /PRNewswire/ -- News Summary: Strong topline performance at the high end of our guidance ranges: Q4 revenue of $14.7 billion, up 8% year over year FY 2025 re...
08-14 04:05
JMP Securities Maintains Market Outperform on Enanta Pharma, Raises Price Target to $25
JMP Securities analyst Roy Buchanan maintains Enanta Pharma (NASDAQ:ENTA) with a Market Outperform and raises the price target from $24 to $25.
08-12 21:02
Enanta Pharma Q3 EPS $(0.85) Misses $(0.81) Estimate, Sales $18.314M Beat $16.264M Estimate
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.81) by 4.94 percent. This is a 20.56 percent increase over losses of $(1.07) per share from
08-12 04:22
FGI INDUSTRIES ANNOUNCES SECOND QUARTER 2025 RESULTS
EAST HANOVER, N.J., Aug. 11, 2025 /PRNewswire/ -- FGI Industries Ltd. (Nasdaq: FGI) ("FGI" or the "Company"), a leading global supplier of kitchen and bath products, today announced results ...
08-12 04:15
XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration
Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases. CAMBRIDGE, Mass., Aug. 6, 2025 /PRNewswir...
08-07 07:56
WESTERN MIDSTREAM TO ACQUIRE ARIS WATER SOLUTIONS
Creates a differentiated Delaware Basin produced-water system, enhancing WES's ability to compete for new business development opportunities. The combined infrastructure creates a fully inte...
08-07 04:05
Entrada Therapeutics Reports Second Quarter 2025 Financial Results
Entrada Therapeutics reported Q2 2025 financial results and highlighted key milestones, including the first patient dosed in the ELEVATE-44-201 study and initiation of ELEVATE-45-201. Multiple clinical trial sites in the U.K. and EU are activated. The company expanded its leadership team with Navid Khan, PhD, and Kiran Patki, MD, to support its growing pipeline. Cash reserves of $354 million are expected to fund operations into Q2 2027. Data from...
08-06 11:00
